RSS-Feed abonnieren
DOI: 10.1055/a-2717-5063
Impact of Obesity on Surgical and Patient-reported Outcomes Following Immediate Lymphatic Reconstruction
Authors
Gefördert durch: IUSM Inclusive Excellence Resident Scholar Program
Gefördert durch: National Institute of Health Sciences K08HL167164

Background: While obesity is a known risk-factor for developing breast cancer–related lymphedema (BCRL) after axillary lymph node dissection (ALND), its impact on outcomes of immediate lymphatic reconstruction (ILR) is yet to be elucidated. The purpose of this study is to assess the influence of obesity on BCRL incidence and patient-reported outcomes (PROs) following ILR. Methods: We retrospectively studied consecutive patients who underwent ILR following ALND between 2017 and 2024 across a university hospital system. BCRL prevalence and condition-specific (LYMPH-Q) quality-of-life performance was compared and correlated via multivariable regression. Results: We identified 172 patients (mean BMI 29.5±6.9 kg/m²) with 72 patients (41.9%) categorized as obese (BMI≥30). BCRL incidence was 7.0% with no significant difference between groups (obese, 8.3% vs. non-obese, 6.0%; p=0.553). In adjusted models, obesity was not associated with higher risk of BCRL (OR, 0.90; 95%CI, 0.23–3.47; p=0.875), surgical complications (OR, 1.18; 95%CI, 0.50-2.74, p= 0.708) or unplanned reoperation (OR, 0.72; 95%CI, 0.29-1.80, p=0.479). However, obese patients showed significantly lower mean scores in the LYMPH-Q symptom scale (66.7 ± 27.7 vs. 84.7 ± 16.8, p=0.004) when compared with non-obese patients. In adjusted models, obesity was associated with independently lower LYMPH-Q symptom scores (, -13.8; 95%CI, -26.7 to -0.81; p=0.038). Conclusions: ILR mitigated the risk of BCRL associated with obesity following ALND. However, obesity remained associated with significantly worse patient-reported lymphedema symptom burden following ILR. These findings highlight a dissociation between objective risk reduction and subjective symptom burden, underscoring the need for integrated assessment and targeted symptom management protocols.
Publikationsverlauf
Eingereicht: 27. Juni 2025
Angenommen nach Revision: 21. September 2025
Accepted Manuscript online:
09. Oktober 2025
© . Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor , NY 10001 New York, USA